The cell and advanced therapy industry has achieved some extraordinary milestones in 2017, culminating with the FDA stating it was committed to encouraging and supporting innovation in the field, and was seeking ways to accelerate the approvals process for new therapies.
With this in mind, cost-effective scale-up and manufacturing remain a key challenge for the industry with a bewildering array of approaches and solutions being pitched to emerging companies. During the Phacilitate Cell & Gene Therapy World Conference in Miami this January, senior members of Invetech’s Cell Therapy Group, David Kneen and Brian Hanrahan, will be joined by industry leaders from Novartis, Kite Pharma and AVROBIO to explore these challenges and discuss the opportunities around selecting a best approach to cost-effective manufacturing and automation.